Market cap
$8,724 Mln
Revenue (TTM)
$288 Mln
P/E Ratio
--
P/B Ratio
15.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-74 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-134.4
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-0.3
-
Face value
--
-
Shares outstanding
279,353,984
10 Years Aggregate
CFO
$-1,216.67 Mln
EBITDA
$-975.31 Mln
Net Profit
$-1,247.80 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ImmunoGen (IMGN)
| 5.3 | 4.9 | 111.6 | 617.9 | 43.7 | 42.3 | 7.0 |
|
BSE Sensex*
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
ImmunoGen (IMGN)
| 497.8 | -33.2 | 15.0 | 26.3 | 6.4 | -25.0 | 214.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ImmunoGen (IMGN)
|
31.2 | 8,724.2 | 287.6 | -73.1 | -27.4 | -21.4 | -- | 15.5 |
| 0.0 | 3.0 | 7.0 | -81.2 | -1,216.8 | -- | -- | 1.7 | |
| 0.0 | 0.5 | 0.0 | -22.0 | -- | -- | -- | 0.4 | |
| 0.0 | 5.8 | 21.0 | -96.1 | -338.3 | -- | -- | 18.5 | |
| 0.0 | -- | 481.6 | -1,440.6 | -91.5 | -- | -- | 0.0 |
Shareholding Pattern
View DetailsAbout ImmunoGen (IMGN)
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting... folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc. Read more
-
President, CEO & Director
Mr. Mark Joseph Enyedy
-
President, CEO & Director
Mr. Mark Joseph Enyedy
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ImmunoGen (IMGN)
What is the current share price of ImmunoGen Inc (IMGN) Today?
The share price of ImmunoGen Inc (IMGN) is $31.23 (NASDAQ) as of 13-Feb-2024 09:30 EDT. ImmunoGen Inc (IMGN) has given a return of 43.68% in the last 3 years.
What is the current PB & PE ratio of ImmunoGen Inc (IMGN)?
Since, TTM earnings of ImmunoGen Inc (IMGN) is negative, P/E ratio is not available.
The P/B ratio of ImmunoGen Inc (IMGN) is 15.53 times as on 13-Feb-2024, a 249 premium to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-5.66
|
8.10
|
|
2021
|
-7.18
|
10.28
|
|
2020
|
-18.48
|
13.76
|
|
2019
|
-6.22
|
-9.98
|
|
2018
|
-4.21
|
59.20
|
What is the 52 Week High and Low of ImmunoGen Inc (IMGN)?
The 52-week high and low of ImmunoGen Inc (IMGN) are Rs -- and Rs -- as of 07-Jun-2026.
What is the market cap of ImmunoGen Inc (IMGN)?
ImmunoGen Inc (IMGN) has a market capitalisation of $ 8,724 Mln as on 13-Feb-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in ImmunoGen Inc (IMGN)?
Before investing in ImmunoGen Inc (IMGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.